Ulotaront
Based on 11 publication(s) in Google Scholar
Ulotaront (SEP-363856; SEP-856) is an orally active, blood-brain barrier-penetrant TAAR1 full agonist with an EC50 of 0.14 µM. Ulotaront is a 5-HT1A agonist and a weak agonist of 5-HT1B and 5-HT7 receptors. Ulotaront state-dependently modulates glutamatergic synaptic transmission in the striatum and hippocampus, reducing spontaneous glutamatergic synaptic activity and enhancing evoked synaptic responses. Ulotaront exhibits antipsychotic-like effects in animal models of schizophrenia and also improves glucose tolerance and reduces body weight by delaying gastric emptying and modulating central neural circuits related to energy balance. Ulotaront can be used in research on schizophrenia and obesity.
The free form of the compound is prone to instability, it is advisable to consider the stable salt form (Ulotaront hydrochloride) that retains the same biological activity.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 1310426-33-5
- 화학식: C9H13NOS
- 분자량:183.27
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Ulotaront
More- Nature. 2024 Jun;630(8015):237-246. [Abstract]
- Nature. 2023 Dec;624(7992):672-681. [Abstract]
- Cell. 2023 Nov 22;186(24):5347-5362.e24. [Abstract]
- Adv Sci (Weinh). 2025 Oct 24:e02079. [Abstract]
- J Med Chem. 2025 Apr 10;68(7):7082-7105. [Abstract]
- Front Pharmacol. 2023 Apr 21:14:1161964. [Abstract]
- Drug Dev Res. 2024 Jun;85(4):e22225. [Abstract]
- World J Biol Psychiatry. 2024 Nov 29:1-18. [Abstract]
- Mol Pharmacol. 2025 Jul 28;107(9):100064. [Abstract]
- Synapse. 2025 Mar;79(2):e70011. [Abstract]
- patent. US20260034119A1.
All 5-HT Receptor Isoforms
More
Biological Activity
제품 설명
|
TAAR1 0.14 μM (EC50) |
5-HT2C Receptor 30 μM (EC50) |
5-HT7 Receptor 6.7 μM (EC50) |
5-HT1B Receptor 15.6 μM (EC50) |
5-HT1A Receptor 2.3 μM (EC50) |
5-HT1D Receptor 0.262 μM (EC50) |
In Vitro
Ulotaront bidirectionally modulates corticostriatal-evoked EPSC amplitude in putative D2 MSNs of acute dorsal striatum brain slices, producing distinctly separate elevated and reduced subpopulations without altering the overall population mean[2].
Ulotaront (30 μM; 10-minute baseline) enhances Schaffer collateral-evoked fEPSP amplitude and initial slope in the CA1 region of acute dorsal hippocampal slices without altering PPR[2].
Ulotaront is a full TAAR1 agonist (EC50 = 0.14 µM, Emax 101%) and a 5-HT1A agonist (EC50 = 2.3 µM), with weak agonist activity at 5-HT1B and 5-HT7[1].
Ulotaront (1-30 μM) reduces the spontaneous firing of CA1 neurons in acute dorsal hippocampal slices in a concentration-dependent manner[2].
Ulotaront (30 μM; last 5 minutes of analysis) reduces spontaneous single-unit firing in the CA1 pyramidal layer of acute dorsal hippocampal slices[2].
Ulotaront (SEP-363856) (10 μM) shows >50% inhibition of specific binding at α2A, α2B, D2, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT7 receptors[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Ulotaront (0.3-10 mg/kg; p.o.; single administration 30 min before intravenous glucose) does not alter intravenous glucose or insulin changes in lean mice[3].
Ulotaront (0.3-10 mg/kg; p.o.; once daily for 35 consecutive days) reduces body weight and improves glycemic control in diet-induced obese mice[3].
Ulotaront (0.3-3 mg/kg; p.o.; once daily for 7 consecutive days after 7 days of prior Olanzapine (HY-14541) administration) reduces body weight gain and food intake in high-fat diet-fed rats after switching from Olanzapine to this drug[3].
Ulotaront (0.3-10 mg/kg; p.o.; single administration 30 min before Acetaminophen (HY-66005) or Phenol Red (HY-D0169)) delays gastric emptying in lean mice and rats[3].
Ulotaront (1-10 mg/kg; p.o.; once daily for 21 consecutive days) reverses corticosterone-induced body weight gain in mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1310426-33-5
-
분자량 183.27
-
화학식 C9H13NOS
-
SMILES
CNC[C@H]1C2=C(C=CS2)CCO1
-
Synonyms
SEP-363856; SEP-856
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Nature
2024 Jun;630(8015):237-246. PMID: 38720072 -
Nature
2023 Dec;624(7992):672-681. PMID: 37935376 -
Cell
2023 Nov 22;186(24):5347-5362.e24. PMID: 37963465 -
Adv Sci (Weinh)
Cortico-Striatal-Midbrain Circuit Dysregulation Underlying MK-801 Induced Impulsivity and the Ameliorative Effects of SEP. [Abstract]2025 Oct 24:e02079. PMID: 41133933 -
J Med Chem
Rational Design of the First Dual Agonist at Trace Amine-Associated Receptor 1 and 5-HT2C Receptors Based on Binding Pocket Similarity for the Treatment of Schizophrenia and Alzheimer's Disease-Related Psychosis. [Abstract]2025 Apr 10;68(7):7082-7105. PMID: 40159850 -
Front Pharmacol
Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment. [Abstract]2023 Apr 21:14:1161964. PMID: 37153799 -
Drug Dev Res
SEP-363856 exerts neuroprotection through the PI3K/AKT/GSK-3β signaling pathway in a dual-hit neurodevelopmental model of schizophrenia-like mice. [Abstract]2024 Jun;85(4):e22225. PMID: 38879781 -
World J Biol Psychiatry
SEP-363856 attenuates CUMS-induced depression-like behaviours and reverses hippocampal neuronal injuries. [Abstract]2024 Nov 29:1-18. PMID: 39610275 -
Mol Pharmacol
Trace amine-associated receptor 1 agonists differentially regulate dopamine transporter function. [Abstract]2025 Jul 28;107(9):100064. PMID: 40840012 -
Synapse
Cellular-Resolution and Bulk-Fluorescence Recordings of Calcium Activity Yield Reciprocal Readouts of In Vivo Drug Efficacy. [Abstract]2025 Mar;79(2):e70011. PMID: 40013455 -
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Ulotaront
- 1310426-33-5
- SEP-363856
- SEP-856
- SEP363856
- SEP 363856
- SEP856
- SEP 856
- SEP-856
- Trace Amine-associated Receptor (TAAR)
- 5-HT Receptor
- Serotonin Receptor
- 5-hydroxytryptamine Receptor
- 5-HT1A
- 5-HT1B
- 5-HT7
- TAAR1
- glutamatergic neurotransmission
- monoaminergic neurotransmission
- obesity
- prepulse inhibition
- schizophrenia
- serotonin receptors
- Inhibitor
- inhibitor
- inhibit